Research ArticleClinical Studies

Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies

MITSUHIRO FURUTA, JUNICHIRO WATANABE, TAKESHI ARAMAKI, AKIFUMI NOTSU and HIROFUMI YASUI
In Vivo January 2020, 34 (1) 275-282; DOI: https://doi.org/10.21873/invivo.11771

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    The response of the liver metastasis. A waterfall plot of patients with metastatic breast cancer measuring the maximum reduction (from baseline) in the sum of the longest diameter of liver metastasis based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (16). CR: Complete response; PR: partial response.

  • Figure 2.
    Figure 2.

    Treatment outcomes. A. The overall survival (OS) stratified by the human epidermal growth factor receptor Type2 (HER2) status. B. The OS in HER2-negative patients classified by period. C. The duration of response of liver metastasis classified by HER2 status. CI: Confidence interval.

  • Figure 3.
    Figure 3.

    The overall survival classified by the number of poor prognostic factors (PPFs) (0 versus 1 versus 2). CI: Confidence interval.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies
MITSUHIRO FURUTA, JUNICHIRO WATANABE, TAKESHI ARAMAKI, AKIFUMI NOTSU, HIROFUMI YASUI
In Vivo Jan 2020, 34 (1) 275-282; DOI: 10.21873/invivo.11771
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords